Corbion

Corbion N.V. (Euronext Amsterdam: CRBN) is the Dutch global leader in lactic acid and its derivatives, used as a natural food preservation ingredient (replacing synthetic preservatives in meats, baked goods and dairy), as the building block for biopolymer PLA bioplastics (via the Total-Corbion PLA joint venture with TotalEnergies in Thailand), and as the feedstock for absorbable medical sutures and bone screws. The company also operates a specialty algae-derived omega-3 nutritional ingredients business under the AlgaPrime brand.

Corbion runs two reporting segments. Functional Ingredients and Solutions (about 75 percent of 1.27 billion euros 2025 revenue) covers natural mold-inhibitor blends for bread (Verdad), antimicrobial blends for fresh meat (Opti.Form), shelf-life extension for prepared foods, and pharma-grade lactic acid for medical applications. Health and Nutrition (about 25 percent) is the AlgaPrime omega-3 business plus biomedical implants. Revenue declined 4.5 percent in 2025 due to normalization of post-Covid food prices and selective pricing givebacks to retain volume in food-preservation contracts.

Corbion has a stable institutional shareholder structure typical of Dutch mid-caps. The largest active holders are APG Asset Management (Dutch pension giant, 5.8 percent), Cobepa (Belgian family-office investment vehicle, 4.5 percent through Sofina), Robeco Sustainable Equities (3.2 percent) and Norges Bank Investment Management (the Norwegian sovereign wealth fund, 2.1 percent). The Cobepa stake has been held since 2017 and is a vote of long-term confidence from one of Europe most respected family offices.

Corbion is held in several global ESG and bioeconomy funds because of the natural food preservation and biopolymer story. Pictet Nutrition, Robeco Circular Economy and NN IP Sustainable Equity are all top-20 holders. Insider activity has been quiet for the past 12 months, with the most recent notable purchase being CEO Olivier Rigaud adding 25,000 shares at 17.20 in May 2025. Management is paid significantly in shares (75 percent of long-term incentive), which aligns with the rumored PLA divestiture decision in 2026.

Corbion trades at 18.60 euros with about 57.7 million shares outstanding, implying a 1.07 billion euros market cap. The 2026 consensus EPS estimate is 1.57 euros (versus the trailing 1.27 euros), putting forward P/E at 11.83 times. EV-to-EBITDA at 7.86 times trailing is significantly below specialty-chemicals peers like Croda (16x) and Givaudan (22x), reflecting commodity-exposure perception rather than underlying franchise quality.

Seven covering analysts have an average target of 23.24 euros, implying 24.96 percent upside. The bull-case targets at 28 euros from ING and 26 euros from Kepler Cheuvreux are anchored on the PLA divestiture scenario, where 700 to 900 million euros of cash returned via special dividend or buyback would compress shares outstanding by 25 to 30 percent. The Q4 2026 decision on PLA strategic options is the key valuation catalyst.

1. Aug 2026: H1 2026 results. Free cash flow inflection. Management has guided for FCF to turn positive of 50 to 80 million euros in H1 2026 versus negative 13 million in H1 2025. Confirmation would support the dividend coverage thesis and lift the multiple.
2. Q4 2026: Total-Corbion PLA divestiture decision. The strategic options review (started end-2024) concludes with either a sale, full Corbion buyout of TotalEnergies stake, or status quo. A clean sale at 1.5 billion euros enterprise value would unlock approximately 700 to 900 million euros for Corbion, supporting a 30 to 50 percent share-price re-rating.
3. Q1 2027: Iowa plant ramp completion. The new Iowa bioethanol-to-lactic-acid plant reaches full capacity by Q1 2027, lifting the US lactic acid supply share from 18 percent to 28 percent and adding 40 to 60 million euros of high-margin revenue.

Corbion is the cleanest play I know on the natural food preservation and bioeconomy thesis with a hard catalyst on the horizon. The PLA divestiture decision in Q4 2026 is potentially worth 6 to 9 euros per share returned to shareholders, on top of the underlying business which is itself worth 18 to 22 euros on normalized free cash flow.

I size CRBN at 1.5 to 2 percent of portfolio as a special-situation value position. Patience required: the PLA decision could slip to 2027, and the FCF inflection in H1 2026 needs to deliver. Downside is mid-teens drawdown if neither catalyst materializes. Upside is 40 to 60 percent over 18 to 24 months if both the operating recovery and the PLA divestiture play out as expected. The 3.44 percent dividend gives you a real coupon while waiting.